Laboratory Corp. of America (NYSE:LH) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, July 25th. Analysts expect Laboratory Corp. of America to post earnings of $2.90 per share for the quarter. Laboratory Corp. of America has set its FY19 guidance at $11.05-11.45 EPS.
Laboratory Corp. of America (NYSE:LH) last issued its earnings results on Tuesday, April 30th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.09. The business had revenue of $2.79 billion during the quarter, compared to analysts’ expectations of $2.82 billion. Laboratory Corp. of America had a net margin of 8.59% and a return on equity of 16.59%. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.78 earnings per share. On average, analysts expect Laboratory Corp. of America to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.
LH opened at $175.97 on Wednesday. The company has a market capitalization of $17.11 billion, a price-to-earnings ratio of 15.97, a P/E/G ratio of 1.58 and a beta of 1.04. Laboratory Corp. of America has a 1-year low of $119.38 and a 1-year high of $185.76. The stock has a 50 day moving average price of $171.38. The company has a current ratio of 1.14, a quick ratio of 1.05 and a debt-to-equity ratio of 0.77.
In other Laboratory Corp. of America news, SVP Der Vaart Sandra D. Van sold 2,328 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $176.75, for a total value of $411,474.00. Following the sale, the senior vice president now owns 2,328 shares of the company’s stock, valued at $411,474. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lisa J. Uthgenannt sold 4,000 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $164.00, for a total value of $656,000.00. Following the completion of the sale, the insider now directly owns 4,638 shares in the company, valued at approximately $760,632. The disclosure for this sale can be found here. Insiders sold 29,191 shares of company stock valued at $4,948,144 in the last quarter. 0.74% of the stock is currently owned by company insiders.
Several equities research analysts have recently weighed in on LH shares. Wolfe Research started coverage on shares of Iqvia in a research note on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Jefferies Financial Group reaffirmed a “sell” rating on shares of Hi-Crush Partners in a research report on Tuesday, April 2nd. Barclays set a $330.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Monday, July 15th. Mizuho set a $31.00 price objective on shares of Evolus and gave the company a “buy” rating in a research report on Monday, May 20th. Finally, UBS Group lowered shares of Advanced Disposal Services from a “buy” rating to a “neutral” rating and set a $33.00 price objective for the company. in a research report on Wednesday, May 1st. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $182.60.
About Laboratory Corp. of America
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Featured Story: How does equity income fit into an investing strategy?
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.